Immutep Limited (IMM.AX) is currently considered not halal (non-compliant), per In-house ratio engine (last assessed 2026-08-28). See the full ratio breakdown and business-activity screen below for the reasoning.
⚠️ Financial ratios are only half the screen. A company whose core business is in an excluded sector — weapons/defense, alcohol, gambling, conventional (interest-based) finance, tobacco, pork, or adult entertainment — is non-compliant even if every debt and income ratio passes. So passing ratios below don't override this verdict; check the business-activity screen for the reason.
Computed from published company financials, balance sheet as of 2025-12-31. IMM.AX files no SEC reports, so these ratios come from the issuer's own published statements rather than XBRL.
Business activity: cleared (no excluded categories detected)
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 1.59% | 30.00% | Pass |
| Interest-bearing investments | 130.20% | 30.00% | Fail |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 1.64% | 33.00% | Pass |
| Interest-bearing investments | 67.34% | 33.00% | Fail |
| Non-liquid assets | 12.34% | at least 20.00% | Fail |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 0.82% | 33.33% | Pass |
| Cash + interest-bearing securities | 67.34% | 33.33% | Fail |
| Accounts receivable | 87.66% | 33.33% | Fail |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 0.82% | 33.33% | Pass |
| Cash + interest-bearing securities | 67.34% | 33.33% | Fail |
| Accounts receivable | 87.66% | 50.00% | Fail |
Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 0.37% | 33.00% | Pass |
| Cash + interest-bearing securities | 30.51% | 33.00% | Pass |
| Accounts receivable | 9.20% | 33.00% | Pass |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 0.34% | 33.00% | Pass |
| Cash + interest-bearing securities | 28.12% | 49.00% | Pass |
| Accounts receivable | 8.48% | 49.00% | Pass |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 0.34% | 33.33% | Pass |
| Cash + interest-bearing securities | 28.12% | 33.33% | Pass |
| Accounts receivable | 36.60% | 49.00% | Pass |
Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 61.50 | NEUTRAL |
| Stochastic %K (14) | 93.33 | SELL |
| CCI (20) | 67.15 | NEUTRAL |
| Williams %R (14) | -6.67 | SELL |
| MACD (12,26,9) | 0.00 | BUY |
| ROC (10) | 12.00 | BUY |
| Momentum (10) | 0.01 | BUY |
| EMA (10) | 0.05 | BUY |
| SMA (10) | 0.05 | BUY |
| EMA (20) | 0.05 | BUY |
| SMA (20) | 0.05 | BUY |
| EMA (30) | 0.05 | BUY |
| SMA (30) | 0.05 | BUY |
| EMA (50) | 0.05 | BUY |
| SMA (50) | 0.05 | BUY |
| EMA (100) | 0.07 | SELL |
| SMA (100) | 0.05 | BUY |
| EMA (200) | 0.16 | SELL |
| SMA (200) | 0.17 | SELL |
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Healthcare · Biotechnology
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. It also develops INSIGHT-003, which is in phase I trial 1L non squamous NSCL; INSIGHT-005 that is in phase I to treat metastatic urothelial cancer; IMP761, which is in phase I Trial to treat autoimmune disease; IMP731 for oncology and autoimmune diseases; and LAG525. Immutep has collaboration with Merck & Co., Inc., EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.
Background via Yahoo Finance — informational, not part of the verdict.
Peer movement computing — it will appear here on its own.
NO DATA 0 buys · 0 sells
NEUTRAL report date 2026-09-01 · Asset managers net 934180 (-19048)
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.